Structured page family:Cost guide
Ziconotide Cost Guide: Insurance, Cash Pay, and Savings
In the United States, Ziconotide costs depend on brand, pharmacy, insurance design, and whether the patient qualifies for manufacturer savings programs.
Active Market
This page is designed for US treatment decisions and uses US-first pricing and savings sources.
Official pricing
Verify current pricing directly on official Prialt pages before starting, because list pricing, self-pay offers, and eligibility terms can change.
Cash-pay reality
Official cash-pay pricing varies by pharmacy and dose. Contact multiple pharmacies or use a prescription discount service for current rates.
Insurance coverage
Commercial coverage for Ziconotide varies by plan and indication. Prior authorization is commonly required.
Savings and coupons
Manufacturer savings programs may reduce out-of-pocket cost for eligible commercially insured patients.
Prior Authorization
Prior authorization is common and may require documentation of diagnosis, prior treatments, and clinical need.
Price Breakdown
List price (monthly)
~$2,500-$3,500/month (drug only)
Average wholesale price
~$2,300-$3,300/month
Pharmacy acquisition estimate
~$2,100-$3,000/month
Typical negotiated rate
~$1,800-$2,500/month
Price per dose
~$85 per 100 mcg vial; ~$425 per 500 mcg vial
Annual cost at list price
~$30,000-$42,000 (drug only; pump and procedure costs additional)
Pharmacy Price Comparison
| Pharmacy | Price Range | Notes |
|---|---|---|
| Specialty pharmacy | $2,300-$3,500/month | Required |
Insurance Coverage Landscape
Commercial plans
~70-80% for refractory pain
Medicare Part D
May be Part B (pump/device)
Medicaid
Case-by-case; requires specialist attestation
VA coverage
Available through pain management
TRICARE
Case-by-case
Employer plan typical tier
Tier 5 specialty; often requires medical necessity review
Prior Authorization Guide
Required Documentation
- •Severe chronic pain diagnosis
- •Failure of oral/transdermal opioids and adjuvants
- •Pain specialist attestation
- •Intrathecal therapy candidate evaluation
Common Denial Reasons
- •Not refractory enough
- •No specialist involvement
- •Plan requires less invasive alternatives first
- •Psychiatric contraindications
Appeal Template Points
- •Refractory to all conventional therapy
- •Pain specialist evaluation attached
- •Intrathecal therapy appropriate
- •No respiratory depression risk (advantage over opioids)
- •Improves quality of life
Expected timeline: 2-4 weeks
Savings Programs and Patient Assistance
Manufacturer PAP
manufacturerEligibility: Uninsured/underinsured
Savings: May provide at reduced cost
Income limit: Case-by-case
Enrollment: complex
Limited program
Generic and Biosimilar Status
No generic currently available
Expected: No generic expected
Cost by Dose
| Dose/Regimen | Monthly | Annual |
|---|---|---|
| 0.1-0.5 mcg/hour | $2,500-$3,000 | $30,000-$36,000 |
| 0.5-0.8 mcg/hour | $3,000-$3,500 | $36,000-$42,000 |
Annual Cost Projection
Year 1
$40,000-$60,000 (includes pump implant)
Year 2
$30,000-$45,000 (maintenance)
Year 3
$30,000-$45,000
Assumptions
- •Implant cost year 1
- •Pump replacement every 5-7 years
Cost-Saving Strategies
- 1.Pump implantation and refills are major costs beyond drug — negotiate bundled pricing with center
- 2.Document exhaustive failed therapies for prior auth
- 3.Consider intrathecal morphine combination if ziconotide alone insufficient (may reduce doses)
- 4.VA and academic pain centers may offer more favorable pricing
International Price Comparison
| Country | Price Range | Notes |
|---|---|---|
| UK | NHS specialized pain service | Limited availability |
Need help comparing ziconotide paths?
Use the provider matcher to package treatment interest, insurance, budget, urgency, and state context before you commit to a prescribing path.
Find a ziconotide providerNext Step
Use the cost calculator
Use provider matching when you need help comparing insured and self-pay treatment paths.
Open tool →Retention Path
Join the Ziconotide tracker waitlist
Capture refill timing, weekly dose history, and symptom notes in one planned workflow.
View tracker landing →Trust Summary
Reviewed 2026-04-27 by PeptideScholar editorial review. This page currently cites 2 official sources.
Pricing, savings eligibility, and coverage rules can change quickly. Verify all current figures and terms directly on official brand pages before acting.
Ziconotide Cost FAQ
Sources
- 1. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain.J Pain Symptom Manage • 2006Claim type: clinicalView source →
- 2. FDA Information on ZiconotideFDA • 2026Claim type: regulatoryView source →
This content is for informational purposes only and does not constitute medical advice.